Intellia Therapeutics to Present at Three Key Investor Conferences in May-June 2026
Event summary
- Intellia Therapeutics will participate in three investor conferences between May 12 and June 3, 2026.
- Fireside chats scheduled at Bank of America Securities (May 12), RBC Capital Markets (May 20), and Jefferies (June 3).
- Webcasts will be available live and replays accessible for 90 days post-event.
- Company focuses on CRISPR gene editing and other core technologies for potentially curative treatments.
The big picture
Intellia Therapeutics' participation in multiple high-profile investor conferences underscores its strategic focus on engaging with the financial community to highlight its advancements in CRISPR gene editing. The biopharmaceutical sector is increasingly competitive, with companies racing to develop durable, curative treatments for severe diseases. Intellia's ability to communicate its technological and clinical development progress will be critical in maintaining investor confidence and securing necessary funding for its ambitious pipeline.
What we're watching
- Pipeline Updates
- How Intellia will leverage these conferences to provide updates on its CRISPR-based pipeline progress.
- Market Positioning
- Whether the company can strengthen its position as a leader in gene editing therapies through these investor engagements.
- Regulatory Insights
- The pace at which Intellia can navigate regulatory hurdles for its experimental treatments.